ArticlePloS one2007
The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction.
Article in PloS one, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.Clinical pharmacology and therapeutics · 2020Guideline
- Twenty-Five Years of Evolution and Hurdles in Electronic Health Records and Interoperability in Medical Research: Comprehensive Review.Journal of medical Internet research · 2025Review
- Leveraging Electronic Dental Record Data for Clinical Research in the National Dental PBRN Practices.Applied clinical informatics · 2020Article
- The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development.Clinical pharmacology and therapeutics · 2018Article
- The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs.Trends in pharmacological sciences · 2017Review
- The Drug Data to Knowledge Pipeline: Large-Scale Claims Data Classification for Pharmacologic Insight.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2016Article
- Rediscovering drug side effects: the impact of analytical assumptions on the detection of associations in EHR data.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2015Article
- Supporting Multi-sourced Medication Information in i2b2.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2015Article
- Making big data useful for health care: a summary of the inaugural mit critical data conference.JMIR medical informatics · 2014Article
- Dynamic clinical data mining: search engine-based decision support.JMIR medical informatics · 2014Article
- Patient stratification and identification of adverse event correlations in the space of 1190 drug related adverse events.Frontiers in physiology · 2014Article
- Reusing electronic patient data for dental clinical research: a review of current status.Journal of dentistry · 2013Review
- A comparison of the empirical performance of methods for a risk identification system.Drug safety · 2013Article
- Medication-wide association studies.CPT: pharmacometrics & systems pharmacology · 2013Article
- Using electronic dental record data for research: a data-mapping study.Journal of dental research · 2013Article
- Pharmacovigilance using clinical notes.Clinical pharmacology and therapeutics · 2013Article
- Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions.Journal of the American Medical Informatics Association : JAMIA · 2013Article
- Article
- Interpreting noncoding genetic variation in complex traits and human disease.Nature biotechnology · 2012Review
- Novel data-mining methodologies for adverse drug event discovery and analysis.Clinical pharmacology and therapeutics · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundCOX-2 selective inhibitors are associated with myocardial infarction (MI). We sought to determine whether population health monitoring would have revealed the effect of COX-2 inhibitors on population-level patterns of MI. METHODOLOGY/PRINCIPAL
findingsWe conducted a retrospective study of inpatients at two Boston hospitals, from January 1997 to March 2006. There was a population-level rise in the rate of MI that reached 52.0 MI-related hospitalizations per 100,000 (a two standard deviation exceedence) in January of 2000, eight months after the introduction of rofecoxib and one year after celecoxib. The exceedence vanished within one month of the withdrawal of rofecoxib. Trends in inpatient stay due to MI were tightly coupled to the rise and fall of prescriptions of COX-2 inhibitors, with an 18.5% increase in inpatient stays for MI when both rofecoxib and celecoxib were on the market (P<0.001). For every million prescriptions of rofecoxib and celecoxib, there was a 0.5% increase in MI (95%CI 0.1 to 0.9) explaining 50.3% of the deviance in yearly variation of MI-related hospitalizations. There was a negative association between mean age at MI and volume of prescriptions for celecoxib and rofecoxib (Spearman correlation, -0.67, P<0.05). CONCLUSIONS/SIGNIFICANCE: The strong relationship between prescribing and outcome time series supports a population-level impact of COX-2 inhibitors on MI incidence. Further, mean age at MI appears to have been lowered by use of these medications. Use of a population monitoring approach as an adjunct to pharmacovigilence methods might have helped confirm the suspected association, providing earlier support for the market withdrawal of rofecoxib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.